Adaptimmune治療公共 ADAP 深 滬
已收盤 09-19 16:00:00 美东时间
1.01
-0.030
-2.88%
華盛通- 最 高1.06
- 今 開1.03
- 成交量 91.94万股
- 最 低 1.00
- 昨 收 1.04
- 總市值 2.49亿
- 52周最高 2.05
- 市盈率 靜 --
- 換手率 0.37%
- 52周最低 0.42
- 委 比 -6.87%
- 總股本 2.47亿
- 歷史最高 21.57
- 量 比 0.89
- 振 幅 5.77%
- 歷史最低 0.42
- 每 手 1
- 風險率 0.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多自爆！千亿市值超级独角兽，把自己“作死”了
10年前，贵为基因疗法“独角兽”的蓝鸟生物，是投资人眼中的香饽饽，但如今，手握3个天价商业化产品的蓝鸟，却被扔进了“垃圾桶”，市值仅剩1亿美元出头。 撰文...
08-22 20:24
三流的药企，一流的药？
转自：氨基观察 作者 | 武月 创新药世界，最不缺的就是颠覆的故事。 从百济神州超越恒瑞医药，成了创新药一哥，再到国产CAR-T、ADC的强势崛起，颠覆不断。...
08-19 20:03
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination wit...
08-13 20:05
Earnings summary: Adaptimmune Therapeutics beats Q2 estimates
More on Adaptimmune Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024 Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript Adaptimmune Q2 2024 Earnings Preview Agile...
08-12 19:30
快讯 | adaptimmune therapeutics 公司季度每股收益为0.04美元；季度收入为1.282亿美元。
Adaptimmune Therapeutics PLC - Qtrly Shr $0.04; Qtrly Revenues $128.2 Mln
08-12 19:08
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
Shares of Ainos, Inc. (NASDAQ:AIMD) rose sharply in today's pre-market trading ...
08-12 18:04
Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update
SEATTLE, WA / ACCESSWIRE / August 8, 2024 / Aptevo Therapeutics Inc. (NASDAQ:AP...
08-08 20:05
Scotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)
In a report released today, George Farmer from Scotiabank maintained a Buy rati...
08-06 20:58
Galapagos downgraded at Raymond James on lack of business development
Reversing modest gains recorded in the previous session following the company’s Q2 results, Galapagos (NASDAQ:GLPG) shares turned lower on Friday as Raymond James downgraded the Belgian biotech, citin...
08-03 01:58
Agilent gets FDA approval for Tecelra companion diagnostic
Agilent (NYSE:A) has received FDA approval for the use of MAGE-A4 IHC 1F9 pharmDx as a diagnostic tool to help identify patients who may be eligible for treatment with Adaptimmune Therapeutics’ (NASDA...
08-03 00:46
